N-Acetyl Semax Amidate

N-Acetyl Semax Amidate Cognitive & Nootropic Overview

N-Acetyl Semax Amidate is a meticulously engineered neurotrophic compound, designed to heavily bias central nervous activity toward synaptic growth, neuronal protection, and optimized cerebral signaling efficiency.

Physiochemical Profile

Parameter	Value
Molecular Formula	C41H54N14O15
Molecular Mass	998.9 g/mol
Assay Purity	>99.0%
Appearance	White-to-off-white solid

Figure 1: N-Acetyl Semax Amidate Blood-Brain Barrier (BBB) Permeation

Cerebral Mechanism of Action

Detailed cascade of actions triggering its primary nootropic effects:

1. Identical neurotrophic peptide chain as original Semax.
2. Features an N-terminal acetylation alongside a C-terminal amidation.
3. Completely shields the compound from blood plasma mono-aminopeptidases.
4. Exponentially increases the half-life and absolute penetration magnitude across the BBB.
5. Creates a sharper, much longer-lasting potentiation of central dopamine signaling.

Figure 2: Rate of Synaptogenesis / BDNF Expression

Primary Research Outcomes

• Finding 1: Considered the apex modification for cognitive focus among the ACTH analogues.
• Finding 2: Greatly reduces required administration frequencies relative to the base peptide.
• Finding 3: Induces a pronounced state of clarity and mental stamina during high-load analytical tasks.

Enhanced Stability & Potency Modifications

N-Acetyl Semax Amidate (NASA) is a double-modified version of the Semax peptide in which the N-terminus is acetylated and the C-terminus is amidated. These pharmaceutical chemistry modifications serve the same purpose as in N-Acetyl Epitalon Amidate: blocking exopeptidase degradation at both termini. For Semax specifically, these modifications are particularly impactful because the unmodified peptide has an extremely short plasma half-life (~3 minutes). The terminal protections extend this half-life significantly and increase the amount of intact peptide reaching CNS targets.

1. N-terminal acetylation blocks aminopeptidase M recognition, preventing N-terminal methionine cleavage that initiates the degradation cascade.
2. C-terminal amidation replaces the free carboxylate with a carboxamide, blocking carboxypeptidase A and B activity.
3. The combined modifications extend the effective half-life from ~3 minutes to an estimated 15–45 minutes, increasing CNS exposure per dose.
4. BDNF upregulation potency may be enhanced due to higher sustained peptide concentrations at hippocampal and cortical target sites.
5. The modifications slightly increase lipophilicity, potentially improving nasal mucosal absorption and blood-brain barrier permeability.

Research Advantages over Standard Semax

• Potency: Users of both forms consistently report NASA as subjectively more potent per milligram, consistent with improved pharmacokinetics rather than altered pharmacodynamics.
• Duration: The extended half-life produces a longer duration of nootropic effect, potentially reducing dosing frequency from 3× daily (standard Semax) to 1–2× daily.
• Lower Effective Dose: Improved bioavailability means less peptide is wasted to proteolytic degradation, allowing lower absolute doses for equivalent CNS exposure.
• Stability: The capped termini also improve storage stability of the reconstituted solution, reducing degradation during the use period.
• Administration: Intranasal, identical technique to standard Semax. Store lyophilized at −20°C; reconstituted solution at 2–8°C.